Exploring dysregulated signaling pathways in cancer

Sabah Nisar, Sheema Hashem, Muzafar A. Macha, Santosh K. Yadav, Sankavi Muralitharan, Lubna Therachiyil, Geetanjali Sageena, Hamda Al-Naemi, Mohammad Haris, Ajaz A. Bhat

Research output: Contribution to journalArticle

Abstract

Cancer cell biology takes advantage of identifying diverse cellular signaling pathways that are disrupted in cancer. Signaling pathways are an important means of communication from the exterior of cell to intracellular mediators, as well as intracellular interactions that govern diverse cellular processes. Oncogenic mutations or abnormal expression of signaling components disrupt the regulatory networks that govern cell function, thus enabling tumor cells to undergo dysregulated mitogenesis, to resist apoptosis, and to promote invasion to neighboring tissues. Unraveling of dysregulated signaling pathways may advance the understanding of tumor pathophysiology and lead to the improvement of targeted tumor therapy. In this review article, different signaling pathways and how their dysregulation contributes to the development of tumors have been discussed.

Original languageEnglish
Pages (from-to)429-445
Number of pages17
JournalCurrent pharmaceutical design
Volume26
Issue number4
DOIs
Publication statusPublished - 1 Jan 2020

    Fingerprint

Keywords

  • Angiogenesis
  • Apoptosis
  • Cell invasion
  • Cell proliferation
  • Drug targets
  • Metastasis
  • Signaling pathways
  • Tumor microenvironment

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

Nisar, S., Hashem, S., Macha, M. A., Yadav, S. K., Muralitharan, S., Therachiyil, L., Sageena, G., Al-Naemi, H., Haris, M., & Bhat, A. A. (2020). Exploring dysregulated signaling pathways in cancer. Current pharmaceutical design, 26(4), 429-445. https://doi.org/10.2174/1381612826666200115095937